167 related articles for article (PubMed ID: 9310492)
1. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.
Ferrari G; Berend C; Ottinger J; Dodge R; Bartlett J; Toso J; Moody D; Tartaglia J; Cox WI; Paoletti E; Weinhold KJ
Blood; 1997 Sep; 90(6):2406-16. PubMed ID: 9310492
[TBL] [Abstract][Full Text] [Related]
2. IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).
Ferrari G; King K; Rathbun K; Place CA; Packard MV; Bartlett JA; Bolognesi DP; Weinhold KJ
Clin Exp Immunol; 1995 Aug; 101(2):239-48. PubMed ID: 7544247
[TBL] [Abstract][Full Text] [Related]
3. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
Gorse GJ; Patel GB; Belshe RB;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1175-89. PubMed ID: 11522187
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
Salmon-Céron D; Excler JL; Finkielsztejn L; Autran B; Gluckman JC; Sicard D; Matthews TJ; Meignier B; Valentin C; El Habib R; Blondeau C; Raux M; Moog C; Tartaglia J; Chong P; Klein M; Milcamps B; Heshmati F; Plotkin S
AIDS Res Hum Retroviruses; 1999 May; 15(7):633-45. PubMed ID: 10331442
[TBL] [Abstract][Full Text] [Related]
5. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.
Engelmayer J; Larsson M; Lee A; Lee M; Cox WI; Steinman RM; Bhardwaj N
J Virol; 2001 Mar; 75(5):2142-53. PubMed ID: 11160718
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.
Gorse GJ; Patel GB; Mandava MD; Belshe RB
Vaccine; 1999 Dec; 18(9-10):835-49. PubMed ID: 10580197
[TBL] [Abstract][Full Text] [Related]
7. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.
Egan MA; Pavlat WA; Tartaglia J; Paoletti E; Weinhold KJ; Clements ML; Siliciano RF
J Infect Dis; 1995 Jun; 171(6):1623-7. PubMed ID: 7769304
[TBL] [Abstract][Full Text] [Related]
8. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
[TBL] [Abstract][Full Text] [Related]
9. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
Evans TG; Keefer MC; Weinhold KJ; Wolff M; Montefiori D; Gorse GJ; Graham BS; McElrath MJ; Clements-Mann ML; Mulligan MJ; Fast P; Walker MC; Excler JL; Duliege AM; Tartaglia J
J Infect Dis; 1999 Aug; 180(2):290-8. PubMed ID: 10395842
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines.
Kaslow RA; Rivers C; Tang J; Bender TJ; Goepfert PA; El Habib R; Weinhold K; Mulligan MJ;
J Virol; 2001 Sep; 75(18):8681-9. PubMed ID: 11507213
[TBL] [Abstract][Full Text] [Related]
11. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.
Carmichael A; Jin X; Sissons P; Borysiewicz L
J Exp Med; 1993 Feb; 177(2):249-56. PubMed ID: 8093890
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.
Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788
[TBL] [Abstract][Full Text] [Related]
14. CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects.
Huang XL; Fan Z; Kalinyak C; Mellors JW; Rinaldo CR
Clin Diagn Lab Immunol; 2000 Mar; 7(2):279-87. PubMed ID: 10702505
[TBL] [Abstract][Full Text] [Related]
15. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals.
Larsson M; Jin X; Ramratnam B; Ogg GS; Engelmayer J; Demoitie MA; McMichael AJ; Cox WI; Steinman RM; Nixon D; Bhardwaj N
AIDS; 1999 May; 13(7):767-77. PubMed ID: 10357375
[TBL] [Abstract][Full Text] [Related]
16. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.
Ferrari G; Humphrey W; McElrath MJ; Excler JL; Duliege AM; Clements ML; Corey LC; Bolognesi DP; Weinhold KJ
Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1396-401. PubMed ID: 9037064
[TBL] [Abstract][Full Text] [Related]
17. Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes.
Kundu SK; Merigan TC
AIDS; 1992 Jul; 6(7):643-9. PubMed ID: 1354446
[TBL] [Abstract][Full Text] [Related]
18. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines.
Carruth LM; Greten TF; Murray CE; Castro MG; Crone SN; Pavlat W; Schneck JP; Siliciano RF
AIDS Res Hum Retroviruses; 1999 Jul; 15(11):1021-34. PubMed ID: 10445814
[TBL] [Abstract][Full Text] [Related]
19. The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope.
Kan-Mitchell J; Bisikirska B; Wong-Staal F; Schaubert KL; Bajcz M; Bereta M
J Immunol; 2004 May; 172(9):5249-61. PubMed ID: 15100263
[TBL] [Abstract][Full Text] [Related]
20. A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
Eller MA; Slike BM; Cox JH; Lesho E; Wang Z; Currier JR; Darden JM; Polonis VR; Vahey MT; Peel S; Robb ML; Michael NL; Marovich MA
PLoS One; 2011; 6(9):e24254. PubMed ID: 21949699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
